- Open Access
Mesenchymal stem cells derived from human induced pluripotent stem cells improve the engraftment of myogenic cells by secreting urokinase-type plasminogen activator receptor (uPAR)
Stem Cell Research & Therapy volume 12, Article number: 532 (2021)
Duchenne muscular dystrophy (DMD) is a severe X-linked recessive disease caused by mutations in the dystrophin gene. Transplantation of myogenic stem cells holds great promise for treating muscular dystrophies. However, poor engraftment of myogenic stem cells limits the therapeutic effects of cell therapy. Mesenchymal stem cells (MSCs) have been reported to secrete soluble factors necessary for skeletal muscle growth and regeneration.
We induced MSC-like cells (iMSCs) from induced pluripotent stem cells (iPSCs) and examined the effects of iMSCs on the proliferation and differentiation of human myogenic cells and on the engraftment of human myogenic cells in the tibialis anterior (TA) muscle of NSG-mdx4Cv mice, an immunodeficient dystrophin-deficient DMD model. We also examined the cytokines secreted by iMSCs and tested their effects on the engraftment of human myogenic cells.
iMSCs promoted the proliferation and differentiation of human myogenic cells to the same extent as bone marrow-derived (BM)-MSCs in coculture experiments. In cell transplantation experiments, iMSCs significantly improved the engraftment of human myogenic cells injected into the TA muscle of NSG-mdx4Cv mice. Cytokine array analysis revealed that iMSCs produced insulin-like growth factor-binding protein 2 (IGFBP2), urokinase-type plasminogen activator receptor (uPAR), and brain-derived neurotrophic factor (BDNF) at higher levels than did BM-MSCs. We further found that uPAR stimulates the migration of human myogenic cells in vitro and promotes their engraftment into the TA muscles of immunodeficient NOD/Scid mice.
Our results indicate that iMSCs are a new tool to improve the engraftment of myogenic progenitors in dystrophic muscle.
Duchenne muscular dystrophy (DMD) is a devastating X-linked muscle disease that is caused by mutations in the DMD gene and affects 1 of 5000 male infants [1, 2]. Boys with DMD exhibit symptoms between 2 and 5 years of age, including delayed motor development, abnormal gait, and muscle weakness . Progressive muscle degeneration leads to loss of ambulation when patients are 8–12 years old and cardio-respiratory failure when patients are in their 20 s and 30 s .
The DMD gene encodes the protein dystrophin. In myofibers, dystrophin is required for assembly of the dystrophin-glycoprotein complex (DGC) at the sarcolemma, and the DGC links the extracellular matrix (ECM) to the cytoskeleton . Myofibers lacking dystrophin are easily damaged by contraction-induced mechanical stress, leading to repeated cycles of necrosis and regeneration of myofibers that result in chronic inflammation and gradual replacement of myofibers with fibrous and fatty tissues . Transplantation of muscle stem/progenitor cells is a potential therapy for DMD, but the transplanted cells do not efficiently engraft and exert the therapeutic effects in the muscle of DMD patients .
In recent years, there has been considerable interest in the clinical application of mesenchymal stem cells (MSCs) for the treatment of muscle diseases. Several groups have demonstrated that transplantation of MSCs, through their paracrine functions, promotes the regeneration of skeletal muscle and ameliorates the dystrophic phenotype in animal models of DMD [6,7,8,9,10,11,12,13]. Therefore, we thought that MSCs might improve the engraftment of human myogenic progenitors by supporting their survival, proliferation, migration, and differentiation into myofibers in a paracrine manner.
MSC-like cells can be derived from human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) [14,15,16]. hESC/hiPSC-derived MSCs are reported to have higher proliferative capacity and to show greater therapeutic effects than tissue-derived MSCs in several disease models [17,18,19]. Therefore, we utilized human hiPSCs to generate MSCs (iMSCs). Here, we report that iMSCs improved the engraftment of human myogenic cells in the TA muscle of immune-dystrophin-deficient NSG-mdx4Cv mice. Our results also suggested that iMSCs increased the engraftment efficiency of myogenic cells by secreting uPAR. iMSCs may aid in the development of cell-based therapies to treat DMD.
Derivation of MSCs from human iPS cells
We derived MSCs from three hiPSC cell lines, 201B7, 454E2, and 409B2, established from healthy donors [20, 21]. Induced MSCs (iMSCs) exhibited a fibroblastic spindle shape on plastic culture dishes (Additional file 1: Fig. 1A, B). Fluorescence-activated cell sorting (FACS) analysis showed that iMSCs expressed the mesenchymal stem cell markers CD73, and CD90, and were negative for the hematopoietic cell markers CD34 and CD45 (Fig. 1A). The expression of CD105 was constantly weaker in iMSCs than in BM-MSCs (Fig. 1A). Immunocytochemistry for FABP4, osteocalcin, and aggrecan indicated that the cells have the potential to differentiate into adipocytes, osteocytes, and chondrocytes under appropriate differentiation conditions (Fig. 1B). Positive staining with Alizarin red and Alcian blue in each differentiation condition further suggests the ability of iMSCs to differentiate into osteogenic and chondrogenic lineages, respectively (Fig. 1C). However, iMSCs differentiated into oil red O-positive adipogenic cells with much less efficiency than BM-MSCs. iMSC cultures were negative for the pluripotency markers OCT3/4, SOX2, and NANOG by immunocytochemistry and RT-qPCR, indicating that there were no residual pluripotent stem cells in the culture (Additional file 1: Fig. 1C, D). Thus, our iMSCs meet the minimal criteria for MSCs defined by the International Society for Cellular Therapy (ISCT) standards . Next, we compared the proliferation of iMSCs to that of BM-MSCs. Crystal violet staining and MTT assays showed that the iMSCs had higher proliferation rates than BM-MSCs (Fig. 1D, E).
iMSCs promoted proliferation and differentiation of human myogenic cells in vitro
Next, we examined the effects of MSCs on human myogenic cells by coculturing MSCs (either iMSCs or BM-MSCs) with human myogenic cells (Hu5/KD3 myoblasts, human primary skeletal muscle myoblasts (hSKMMs), or hiPSC-derived muscle progenitors) in a Transwell system (Fig. 2). In the Transwell system, MSCs and myogenic cells do not come into contact directly, allowing assessment of the effects of paracrine factors released from the MSCs on myogenic cells. Both iMSCs and BM-MSCs promoted the proliferation (Additional file 1: Fig. 2) of human myogenic cells (Hu5/KD3 cells). The effects on hiPSC-MPs were not statistically significant. The hSKMMs proliferated slowly, and their proliferation was not stimulated by coculture with MSCs. The higher fusion index at day 7 indicated that both iMSCs and BM-MSCs promoted the fusion of Hu5/KD3 cells and human skeletal myogenic cells (hSKMMs) at day 7. These results indicate that both iMSCs and BM-MSCs have similar abilities to promote the proliferation and differentiation of human myogenic cells in the Transwell coculture system (Fig. 2B, C).
iMSCs improved engraftment of Hu5/KD3 myogenic cells in skeletal muscle of NSG-mdx4Cv mice
Next, we examined whether MSCs support the engraftment of myogenic cells. A previous report showed that bone marrow-derived mesenchymal stromal cells injected into the peritoneal cavity ameliorated the pathology of dystrophin/utrophin double-knockout mice, a mouse model of severe DMD . Therefore, to evaluate the paracrine effects of these cells, we first cocultured human myogenic cells with either BM-MSCs or iMSCs in a Transwell coculture system for four days, then transplanted MSCs intraperitoneally (IP) and transplanted the myogenic cells directly into the TA muscles of immuno-dystrophin-deficient NSG-mdx4CV mice . One day before the cell transplantation, both the right and left TA muscles were injected with 1.2% BaCl2 solution to damage the myofibers and induce muscle regeneration. We prepared five experimental groups for cell transplantation (Fig. 3). For the first group, 10% Matrigel in PBS was injected to the left TA muscle as a control. For the second group, Hu5/KD3 human myogenic cells were injected into the left TA muscle. For the third group, Hu5/KD3 myogenic cells were injected into the left TA muscle, and hiPSC-derived MSCs were transplanted intraperitoneally. For the fourth group, Hu5/KD3 cells were injected into the left TA, and BM-MSCs were injected intraperitoneally. For the fifth group, Hu5/KD3 cells were co-cultured with iMSCs for four days and then transplanted into the left TA muscle. For groups 3 and 4, MSCs were injected into the peritoneal cavity once per week for three weeks (4 IP injections in total) (Fig. 3B).
Four weeks after the transplantation of myogenic cells, the mice were killed, and the TA muscles were dissected and examined for engraftment of myogenic cells. Myofibers repaired by myogenic cells were detected by immunohistochemistry with dystrophin antibody and anti-human lamin A/C antibody. To exclude naturally occurring revertant dystrophin-positive fibers in NSG-mdx4Cv mice , we counted dystrophin-positive (sarcolemma), and human lamin A/C-positive (nuclear membrane) myofibers (Fig. 3C, D). Intraperitoneal injection of iMSCs but not BM-MSCs increased the number of double-positive myofibers in TA muscles (Fig. 3C, D). The results were also confirmed by double staining with human spectrin (sarcolemma) and human lamin B1 staining (Additional file 1: Fig. 3A). No human lamin A/C-positive myofibers were found in the Matrigel-PBS-injected right TA muscles of any experimental group, indicating that MSCs injected into the peritoneal cavity did not migrate to the TA muscle and fuse to damaged myofibers there (Fig. 3C). Importantly, single transplantation of Hu5/KD3 cells, which had been co-cultured with iMSCs in Transwell plates, also showed numbers of double-positive myofibers comparable to co-transplantation with iMSCs (IP), suggesting that exposure to soluble factors from iMSCs was enough to improve the engraftment of human myogenic cells (Fig. 3D).
We also injected Hu5/KD3 myogenic cells into the TA muscles of immunodeficient NOD/Scid mice. The intraperitoneal injections of iMSCs also showed a tendency to promote engraftment of the Hu5/KD3 cells into the TA muscles of NOD/Scid mice, although this difference was not statistically significant (Additional file 1: Fig. 3B).
Intraperitoneal transplantation of BM-MSCs and iMSCs reduced fibrosis of the diaphragm in NSG-mdx4Cv mice
We also evaluated the effects of iMSCs on dystrophic pathology because MSCs have been reported to improve the dystrophic phenotype via paracrine effects throughout the body [6,7,8,9,10,11,12,13]. The grip test and treadmill test administered to mdx mice peritoneally injected with iMSCs showed a tendency of improvement of muscle function, but there was statistically no significant difference between control and treated mdx mice (Additional file 1: Fig. 4A, B). Hematoxylin and eosin (H.E.) staining showed no obvious improvement in the pathology of the right TA muscles, which were not injected with Hu5/KD3 cells, in NSG-mdx4Cv mice or of mdx mice (data not shown). We compared the fiber cross-sectional area (CSA) in the right TA muscles in all groups; again, there was no significant difference in fiber sizes among all three groups (Additional file 1: Fig. 4A, B). Likewise, there was no significant difference in the CSA distribution of myofibers in the TA muscles between the treated and non-treated mdx mice (Additional file 1: Fig. 5C–E).
Mdx mice generally show a milder dystrophic muscle phenotype than DMD patients; however, the diaphragm of mdx mice shows progressive loss of myofibers and severe fibrosis. Therefore, we evaluated the fibrosis of the diaphragm in NSG-mdx4CV mice with Sirius red staining. Surprisingly, the fibrous areas in the diaphragms of mice that received intraperitoneal injections of either iMSCs or BM-MSCs were significantly reduced compared to those of controls (Additional file 1: Fig. 4C, D). The Sirius red-stained area in the TA muscles was also examined; however, there was no significant difference between the iMSC- or BM-MSC-injected groups and the controls (data not shown).
iMSCs and BM-MSCs produce different cytokines
To understand the mechanisms by which iMSCs improved engraftment of myogenic cells, we examined the cytokines secreted by iMSCs or BM-MSCs into the culture medium using a membrane-based human cytokine antibody array containing 120 targets. BM-MSCs and iMSCs strongly expressed many shared cytokines (TIMP-2, MCP-1, IL-8, TIMP-1, SDF-1a, IGFBP6, and TNFR1). However, iMSCs showed higher expression of IGFBP2, uPAR, and BDNF than BM-MSCs. BM-MSCs expressed osteoprotegerin (OPG) and IL-6 at higher levels than iMSCs (Table 1, Additional file 1: Fig. 6).
uPAR stimulated migration of human myogenic cells in vitro and improved their engraftment in TA muscle of NOD/Scid mice
Finally, we tested whether uPAR, BDNF, or IGFBP2 promotes the engraftment of myogenic cells into immunodeficient NOD/Scid mice. Recombinant human uPAR and BDNF but not IGFBP2 protein stimulated the migration of human myogenic cells in vitro (Fig. 4A, Additional file 1: Fig. 6), while the proliferation of the cells (MTT assay) and differentiation (muscle myosin heavy chain staining) of the cells were not improved by uPAR, BDNF, or IGFBP2 (Fig. 4B, C). To examine the effects of uPAR, BDNF, or IGFBP2 on the engraftment of transplanted myogenic cells, we cultured Hu5/KD3 cells in 10% FBS/DMEM supplemented with uPAR, BDNF, or IGFBP2 at a concentration of 20 ng/ml for 3 days, suspended the cells in a buffer containing 5 μg/ml recombinant uPAR or BDNF and 5% Matrigel, and injected the suspension into the TA muscles of NOD/Scid mice. Immunohistochemical analysis using human lamin A/C antibody and human spectrin antibody revealed that only uPAR significantly improved the engraftment of Hu5/KD3 cells in the TA muscle of NOD/Scid mice (Fig. 5A, B). To clarify the mechanisms by which uPAR improved the engraftment of myogenic cells, we tested whether urokinase-type plasminogen activator (uPA) enhanced the effects of uPAR on cell engraftment. Interestingly, recombinant uPA stimulated migration of myogenic cells (Fig. 5C) and further increased the number of human lamin B1-positive, human spectrin-positive myofibers in the host muscle (Fig. 5D, E).
Finally, we knocked down uPAR expression in 454E2-hiPSC-derived MSCs using shRNA plasmids (Fig. 6). A cocktail of three plasmids reduced the expression of uPAR 30–60% at the protein level (RT-qPCR) and 20–70% at the mRNA level (Western blotting) (Fig. 6). The knockdown of uPAR in iMSCs reduced the efficiency of cell transplantation, suggesting that iMSC-derived uPAR plays a major role in promoting the engraftment efficiency of myogenic cells.
To understand the mechanisms by which uPAR improved cell engraftment, we added a recombinant human plasminogen activator inhibitor-1 (PAI-1), a natural inhibitor of uPA, to the co-culture medium (100 ng/ml). As expected, PAI-1 reduced the efficiency of cell transplantation (Fig. 6E). This observation supports our hypothesis that iMSCs improved cell engraftment through activation of uPA by uPAR.
Transplantation of muscle stem/progenitor cells is a potential approach to treat DMD, but it faces many challenges. One factor that inhibits successful transplantation of muscle stem/progenitor cells is the hostile microenvironment caused by pathological changes in the DMD muscle [12, 13]. MSCs are unique multipotent stem cells in that they possess not only multipotent differentiation ability but also have paracrine functions that support muscle regeneration by promoting the activation, proliferation, and differentiation of muscle stem/progenitor cells as well as modulating immune responses [6,7,8,9,10,11,12,13]. However, MSCs isolated from tissues have limited proliferative potential for expansion in culture while maintaining their regenerative function . In contrast, MSCs induced from human pluripotent stem cells were reported to expand for up to 40 passages (120 population doublings) without loss of plasticity or replicative senescence . Therefore, we induced iMSCs from hiPSCs and tested whether these iMSCs improve the engraftment of human myogenic cells transplanted into mdx muscle.
iMSCs exhibited a fibroblast-like spindle shape on plastic dishes, expressed the MSC markers CD73, CD90, and CD105, and differentiated into three mesenchymal lineages: osteogenic, adipogenic, and chondrogenic cells. The higher proliferation activity and poorer adipogenic differentiation of iMSCs than BM-MSCs are in agreement with recent reports [25, 26].
Our coculture experiments using a Transwell system showed that both iMSCs and BM-MSCs stimulated the proliferation of myogenic cells and their differentiation to similar extents. Previous reports have shown that MSCs secrete many kinds of cytokines [27, 28]. Our results also indicated that iMSCs and BM-MSCs secrete a variety of cytokines, growth factors, and chemokines (Table 1, Additional file 1: Fig. 6). Therefore, it is likely that such soluble factors promoted the proliferation and differentiation of human myogenic cells in our coculture system.
Intraperitoneal injection of iMSCs or BM-MSCs significantly reduced fibrosis in the diaphragm in NSG-mdx4Cv and mdx mice. We identified several cytokines, such as TIMP1, TIMP2, IL-8, SDF-1a, MCP-1, IGFBP6, and sTNFR1, as candidate factors contributing to the reduction of fibrosis in the diaphragm of NSG-mdx4Cv and mdx mice. TIMP1/2, natural inhibitors of matrix metalloproteinases (MMPs), are good candidates because upregulation of MMP9 is reported to promote fibrosis in muscular dystrophy .
iMSCs promoted the engraftment of human myoblasts (Hu5/KD3 cells) in the TA muscle of NSG-mdx4Cv mice. We cocultured Hu5/KD3 cells with iMSCs for four days before transplantation. Because co-culture with iMSCs enhanced the engraftment of myogenic cells, we think that exposure to soluble factors from iMSCs was critical for improving cell engraftment.
To identify engraftment-promoting factors, we examined the cytokines secreted by BM-MSCs and iMSCs by using a cytokine array. Although BM-MSCs and iMSCs showed similar cytokine expression patterns, iMSCs expressed uPAR, BDNF, and IGFBP2 at higher levels than BM-MSCs. To determine which cytokines promoted engraftment of the cells, we tested the effects of recombinant cytokines on the proliferation, differentiation, and migration of human myogenic cells in vitro. Interestingly, recombinant uPAR and BDNF significantly increased the motility of Hu5/KD3 cells on collagen-coated culture plates. In contrast, the effects of these factors on cell proliferation or differentiation were not evident in our in vitro system.
Although both uPAR and BDNF stimulated the migration of Hu5/KD3 cells in vitro, only uPAR promoted the engraftment of myogenic cells into the TA muscles of NOD/Scid mice (Fig. 5). Interestingly, recombinant uPA also stimulated migration of myogenic cells in a wound-healing assay in vitro and further enhanced the effects of uPAR in vivo. uPA and its receptor uPAR initiate a series of proteolytic cascades that degrade components of the extracellular matrix and enhance the migration of a variety of cells . Migrating, undifferentiated myoblasts have also been reported to express uPA and uPAR. Furthermore, previous studies demonstrated that uPA/uPAR facilitates the proliferation, migration, and fusion of muscle satellite cells or myoblasts [31,32,33,34,35].
Our co-culture experiments, however, suggested that iMSC-derived soluble factors acted directly on human myogenic cells rather than acting on the microenvironments of the host muscle. In addition, human and mouse uPAR share approximately 60% amino acid sequence identity and the receptor-ligand interaction is highly species-specific , suggesting that iMSC-derived uPAR interacted with human uPA and potentiated Hu5/KD3 myogenic cells in co-culture to survive and regenerate myofibers in the host muscle. In clinical settings, however, human uPAR would activate endogenous uPA and further promote engraftment of myogenic cells.
We induced MSC-like cells from human iPSCs (iMSCs). iMSCs promoted the engraftment of human myogenic cells in the TA muscles of NSG-mdx4Cv mice. Our results suggested that iMSCs promoted the engraftment of human myogenic cells via secretion of uPAR. iMSCs, which possess properties distinct from those of BM-MSCs, are a promising new tool for cell therapies to treat Duchenne muscular dystrophy.
Materials and methods
Induction of myogenic cells from hiPSCs
201B7, 409B2, and 454E2 iPSCs were provided by S. Yamanaka at Kyoto University. 201B7 was generated from a healthy donor using retroviral vectors . 409B2 and 454E2 were integration-free hiPS clones generated from healthy donors using episomal vectors . hiPSCs were cultured on iMatrix-511 (Nippi)-coated 6-well plates in StemFit AK02N medium (Ajinomoto) supplemented with penicillin/streptomycin/amphotericin B (1% v/v) (FujiFilm) as described previously [37, 38]. Myogenic cells were induced from hiPSCs as described [37, 38]. After floating culture, cells were induced to differentiate into myogenic cells on collagen type I-coated 10-cm dishes (Iwaki) in 10% FBS (Gibco)/DMEM (FujiFilm) in the presence of 1 μM SB431542 (Wako) for one week. The induced cells were then collected and incubated with ERBB3-APC (1B4C3, BioLegend), CD57(HNK-1)-PE (clone TB03, Miltenyi Biotec), and CD271-BB515 (C40-1457, BD Pharmingen). Myogenic cells were sorted as the CD57(-) CD271(+) ERBB3(+) fraction [37, 38].
Derivation of mesenchymal stem cells from hiPSCs (iMSCs)
MSCs were induced from hiPSCs using the STEMdiff Mesenchymal Progenitor kit (Stemcell Technologies) according to the manufacturer’s protocol. In brief, hiPSCs were first induced into early mesoderm progenitor cells with STEMdiff Mesenchymal Induction Medium. Four days later the medium was changed to MesenCult-ACF medium. The cells were then passaged into 6-well plates coated with MesenCult-ACF Attachment Substrate. At day 24, the induced cells were analyzed for cell surface markers, proliferative potential, and differentiation potential. In this study, iMSCs were used between passages 4 and 8.
Human bone marrow MSCs (BM-MSCs)
BM-MSCs were purchased from Lonza (PT-2501) and cultured on gelatin-coated 6-well plates (Iwaki) using MSCGM Mesenchymal Stem Cell Growth Medium BulletKit (Lonza). Cells were used between passages 4 and 8.
shRNA knockdown experiments
To reduce uPAR expression in iMSCs, we transfected 454E2-iMSCs with uPAR shRNA plasmids (human) (Santa Cruz sc-36781-SH) or control shRNA plasmids (human) (sc-108060) using FuGENE HD (Promega). For selection of transfected cells, puromycin (Millipore) was added to the culture medium at a concentration of 1 ug/ml for 24 h. Knockdown efficiency was evaluated by RT-qPCR and Western blotting as described [37, 38]. For Western blotting, a mouse monoclonal antibody against full length human uPAR protein (E-3, Santa Cruz) was used. After incubation with a second antibody and ECL reaction, the signal was recorded and quantitated with BIO-RAD ChemiDoc MP imaging system.
Human myogenic cells
Hu5/KD3 cells are a human myoblast cell line . The cells were cultured on collagen-coated dishes (Iwaki) in high-glucose DMEM (FujiFilm) supplemented with 20% FBS (Gibco) and 2% Ultroser G (Biosepta, Pall) as previously described . Adult human skeletal muscle myoblasts (hSKMM) were obtained from Lonza (#CC-2580) and cultured on collagen-coated dishes (Iwaki) in 10% FBS/high glucose DMEM. Recombinant human uPAR protein (R&D Systems), recombinant BDNF (Peprotech), or recombinant IGF-BP2 (Peprotech) was added to the culture at different concentrations (2.5, 5.0, 10, 20, or 50 ng/ml).
The cells were plated in 24-well collagen-coated plates at different cell densities: 5 × 104, 7.5 × 104, and 1.0 × 105 cells per well (n = 3 for each group). The next day, 0.1 ml of 0.5% MTT solution was added per well and incubated for 3 h in a CO2 incubator. After aspiration of the medium, 1.0 ml of acid isopropanol was added to each well, and then the well contents were transferred to 1 ml tubes and centrifuged. The absorbance intensity of the supernatant at OD590 nm was measured in a plate reader (BioTek).
Wound healing migration assay
Hu5/KD3 cells were seeded at a density of 1.0 × 106 cells/well in 6-well collagen-coated plates (Iwaki) in 10% FBS/DMEM supplemented with cytokines at different concentrations (0–50 ng/ml). The next day, a straight scratch was made in individual wells with a sterile 200 μl pipette tip and photographed with an Olympus DP21 attached to an Olympus CKX41 inverted light microscope. After 6 h of culture in a CO2 incubator, the cells were again photographed (6 views/condition), and the gaps were measured with ImageJ software.
Trilineage differentiation of MSCs
The trilineage differentiation potential of induced MSCs was examined using a human mesenchymal stem cell functional identification kit (R & D Systems) according to the manufacturer’s protocols.
Cells were seeded at a density of 4.2 × 103 cells/cm2 in αMEM basal medium in collagen-coated 24-well plates, and were cultured in a 5% CO2 incubator at 37 °C. When the cells reached 50–70% confluency, the medium was replaced with osteogenic differentiation medium. After 21 d, the cells were fixed for immunostaining or Alizarin red S staining (Sigma).
Cells were seeded at a density of 2.1 × 104 cells/cm2 in αMEM basal medium in collagen-coated 24-well plates and cultured in a 5% CO2 incubator at 37 °C. When the cells had grown to 100% confluence, the medium was replaced with 0.5 mL of adipogenic differentiation medium. After 21 d, the cells were fixed for immunostaining or Oil red O staining (Sigma). Nuclei were counterstained with Harris’ hematoxylin.
Cells (2.5 × 105) were centrifuged at 200 × g for 5 min at RT in a 15-mL conical tube and resuspended in 1.0 mL of D-MEM/F-12 basal medium. The cells were again centrifuged, resuspended in 0.5 mL of chondrogenic differentiation medium, and centrifuged to form a cell pellet. The pellets were incubated upright in a 5% CO2 incubator at 37 °C. After 21 d, the chondrocyte pellets were fixed and sectioned.
Cells were fixed in 4% paraformaldehyde for 10 min and treated with 0.1% Triton X-100 for 10 min at RT. After blocking with 5% goat serum (Cedarlane)/2% bovine serum albumin (BSA; Sigma) in PBS, the cells were reacted with primary antibodies: a rabbit polyclonal myogenin antibody (Santa Cruz Biotechnology) and an anti-pan myosin heavy chain (MHC) antibody, MF20 (R&D Systems) at a 1:200 dilution overnight at 4 °C. To detect the differentiation of MSCs, an anti-human osteocalcin antibody (R&D Systems, #967801), an anti-mouse FABP4 antibody (R&D Systems, #967799), or an anti-human aggrecan antibody (R&D Systems, #967800) was used. For detection of undifferentiated human iPS cells, an anti-hSOX2 antibody (Cell Signaling, #3579), anti-hNANOG antibody (R&D Systems, AF1997), or an anti-hOCT-3/4 antibody (R&D Systems, AF1759) was used. The next day, after washing with PBS (−), the cells were incubated with Alexa 568 goat anti-mouse IgG2b, Alexa 488 goat anti-rabbit IgG, Alexa 568 donkey anti-goat IgG, or Alexa 488 donkey anti-mouse IgG (Molecular Probes) for 2 h. The nuclei were then stained with DAPI (Tokyo Chemical Industry). The images were recorded with an all-in-one microscope (BZ-X810) and analyzed with hybrid cell count software (Keyence).
RNA isolation, cDNA synthesis, and qPCR
RT-qPCR was performed as previously described [37, 38]. RNA was isolated from cells with TRIzol (Invitrogen) or an RNeasy Mini Kit (Qiagen) and reverse-transcribed into cDNA using a PrimeScript RT reagent kit (Perfect Real Time, Takara). cDNA was amplified with SYBR Premix EX Taq II (Til RNaseH Plus, Takara) and the primer sets listed in Additional file 1: Table 1. The signal was monitored with a CFX Connect Real-Time System (Bio-Rad), and ΔCt (1/2^ (Cq of the gene-median Cq)) was calculated. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) signal was used for normalization.
Cells were incubated with antibodies diluted as suggested by the suppliers in 200 μl of PBS containing 2% FBS (wash buffer) for 30 min on ice, washed in wash buffer, and analyzed using a FACSAria Fusion cell sorter (BD Biosciences). For analysis of iMSCs, CD73-PE (clone AD2, BD Pharmingen), CD105-FITC (clone 266, BD Pharmingen), CD90-PE-Cy7 (clone 5E10, BD Pharmingen), CD34-APC (clone 581, BD Pharmingen), and CD45-APC (clone HI30, BD Pharmingen) were used. The results were analyzed using BD FlowJo software (v.10).
Coculture in a transwell system
MSCs were plated on Transwell inserts (3.0-µm pore polycarbonate; Corning). These inserts were placed in collagen-coated 12-well plates (Iwaki) already containing cultured human myogenic cells at a ratio of 1:1 for 4 d or 1 wk using 10% FBS/DMEM. To evaluate cell proliferation, nuclei were stained with DAPI and counted using Keyence hybrid cell count software. For evaluation of differentiation, the fusion index was calculated: myogenin-positive nuclei inside the myotubes/total nuclei × 100%. Recombinant human plasminogen activator inhibitor (PAI-1) (Sigma-Aldrich) was added to the culture medium at 100 ng/ml.
Mice and cell cotransplantation
NSG-mdx4cv mice  were kindly provided by M. Kyba of the University of Minnesota. C57BL/6-background mdx mice were a generous gift from T. Sasaoka (Niigata University, Japan). NOD/Scid mice (NOD/ShiJic-scidJcl), which lack T- and B-cell function and have decreased natural killer (NK) cell activity, complement activity, and macrophage function, were purchased from CLEA Japan, Inc.
Under general anesthesia with isoflurane, both right and left TA muscles of NSG-mdx4Cv, mdx, or NOD/Scid mice were injured by direct injection of a solution of 1.2% BaCl2 in PBS (50 μL/TA). Myogenic cells were injected into the left TA muscles one day later. First, the myogenic cell cultures were dissociated with 0.05% trypsin–EDTA (Gibco) and resuspended in 10% Matrigel (Corning)/PBS. Under general anesthesia, 60 μL of a cell suspension containing 5 × 105 myogenic cells was injected into the left TA muscle of 6-month-old NSG-mdx4cv male mice or NOD/Scid male mice (3–5 months old) using a 27 G syringe (Terumo). For a negative control, 60 μL of 10% Matrigel/PBS was injected into the right TA muscle. At the same time, 300 μL of a cell suspension containing 1 × 106 MSCs (iMSCs or BM-MSCs) was injected into the intraperitoneal cavity of the mice using a 29 G syringe. For a negative control, PBS vehicle was injected intraperitoneally. The intraperitoneal MSC injections were repeated once per week for the next 3 wks (4 times in total). To examine the effects of uPAR on cell transplantation, Hu5/KD3 cells were cultured for 3 D in 10% FBS/DMEM supplemented with 20 ng/ml recombinant uPAR. Recombinant uPA (1310-SE, R&D Systems) was also added to the culture 24 h before transplantation at a concentration of 20 ng/ml. The cells (1.5 × 106 cells/TA) were then suspended in 50 μl of PBS buffer containing 5% Matrigel and 5 μg/ml uPAR with or without 5 μg/ml uPA and injected into the TA muscles of NOD/Scid mice that had been preinjured one day earlier with 1.2% BaCl2 solution.
Histopathological and immunohistochemical analysis
TA muscles and diaphragms were frozen in liquid nitrogen-cooled isopentane, cut into 10-μm sections with a cryostat, and analyzed as previously described [37, 38]. For immunohistochemical staining, the tissue sections were fixed for 10 min in chilled acetone and air-dried. After blocking with 5% goat serum/2% BSA in PBS, the sections were incubated overnight at 4 °C with primary antibodies: anti-human lamin A/C (Santa Cruz), anti-human spectrin (Leica), anti-laminin α 2 chain (clone 4H8-2, Enzo Life Sciences), anti-human lamin B1 (rabbit polyclonal, HistoSure), or anti-dystrophin antibody (rabbit polyclonal, Abcam) (1:100–1:400 dilution). The next day, after washing with PBS, the sections were incubated with fluorescence-labeled secondary antibodies (Alexa 488 goat anti-mouse IgG2b and Alexa568 goat anti-rabbit IgG (Molecular Probes) or Alexa568 goat anti-rat IgG (Molecular Probes)) for 2 h and mounted in Vectashield with DAPI (Vector Laboratories, Inc). Images were recorded with a Keyence microscope BZ-X810. For evaluation of cell engraftment into dystrophin-deficient mdx muscles, human lamin A/C (+) dystrophin (+) double-positive myofibers were counted. For CSA measurement, 6 images (200X original magnification) stained with anti-laminin α2 chain antibody from a transverse section of one TA muscle (3 TA muscles/group) were randomly selected. To evaluate fibrosis, the Sirius red-stained area was calculated from three random images/TA (100X original magnification) and analyzed using hybrid cell count software (Keyence).
Cytokine levels in culture media were examined using a Human Cytokine Antibody Array (120 targets, Abcam, Cambridge, UK) according to the manufacturers’ instructions. Culture media were harvested from 80–90% confluent cultures of iMSCs derived from 201B7 or 409B2 iPSCs and BM-MSCs. Unused medium (10% FBS/DMEM) was used as a background control. Signals were detected using a ChemiDoc MP Imaging System (Bio-Rad). Data were analyzed with Image Lab 6.0 (Bio-Rad).
Functional assessment of mdx muscle
The grip strength of mice was measured using a force transducer (Model MK-380 M, Muromachi Kikai). The treadmill running test was performed on a Muromachi Model MK-680 (Muromachi Kikai). After 3 wks of acclimatization, the mice (n = 3/group) were subjected to exhaustion tests at 5° inclination with the following protocol: 5 min at 5 m/min followed by incremental speed increases of 1 m/min every 3 min until the mice were exhausted. Exhaustion was defined as the fourth time a mouse spent 5 s on the shocker plate without attempting to re-engage the treadmill.
Data were analyzed and plotted using Prism 8 software (ver. 8.4.0, GraphPad). Means ± SDs or means ± SEMs are shown. Two experimental groups were compared by an unpaired two-tailed Student’s t-test. Multiple groups were compared by one-way ANOVA with Sidak’s multiple comparisons test or Dunnett’s test. *, **, ***, and **** indicate p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively.
Availability of data and materials
Data set supporting our findings and materials are available from the corresponding author on request.
Brain-derived neurotrophic factor
Cross sectional area
Duchenne muscular dystrophy
Dulbecco’s modified Eagle’s medium
Insulin-like growth factor binding protein 2
Fetal bovine serum
Glyceraldehyde 3-phosphate dehydrogenase
Human induced pluripotent stem cells
Human embryonic stem cells
Induced mesenchymal stem cells
Insulin-like growth factor-binding protein 2
Reverse transcriptase polymerase chain reaction
Severe combined immune deficiency
Standard error of the mean
Urokinase-type plasminogen activator receptor
Urokinase-type plasminogen activator
Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919–28.
Mendell JR, Lloyd-Puryear M. Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve. 2013;48:21–6.
Ozawa E. Our trails and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86:798–821.
Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019;15:373–86.
Hodgetts SI, Beilharz MW, Scalzo AA, et al. Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or NK1.1+ cells. Cell Transplant. 2000;9:489–502.
Pinheiro CH, de Queiroz JC, Guimaraes-Ferreira L, et al. Local injections of adipose-derived mesenchymal stem cells modulate inflammation and increase angiogenesis ameliorating the dystrophic phenotype in dystrophin-deficient skeletal muscle. Stem Cell Rev. 2012;8:363–74.
Natsu K, Ochi M, Mochizuki Y, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote the regeneration of injured skeletal muscle without differentiation into myofibers. Tissue Eng. 2004;10:1093–112.
Maeda Y, Yonemochi Y, Nakajyo Y, et al. CXCL12 and osteopontin from bone marrow-derived mesenchymal stromal cells improve muscle regeneration. Sci Rep. 2017;7:3305.
Klimczak A, Kozlowska U, Kurpisz M. Muscle stem/progenitor cells and mesenchymal stem cells of bone marrow origin for skeletal muscle regeneration in muscular dystrophies. Arch Immunol Ther Exp (Warsz). 2018;66:341–54.
Nakamura Y, Miyaki S, Ishitobi H, et al. Mesenchymal-stem-cell-derived exosomes accelerate skeletal muscle regeneration. FEBS Lett. 2015;589:1257–65.
Shabbir A, Zisa D, Leiker M, et al. Muscular dystrophy therapy by nonautologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation. Transplantation. 2009;87:1275–82.
Ichim TE, Alexandrescu DT, Solano F, et al. Mesenchymal stem cells as anti-inflammatories: Implications for treatment of Duchenne muscular dystrophy. Cell Immunol. 2010;260:75–82.
Elhussieny A, Nogami K, Sakai-Takemura F, et al. Mesenchymal stem cells for regenerative medicine for Duchenne muscular dystrophy. IntechOpen. 2020. https://doi.org/10.5772/intechopen.92824.
Steens J, Klein D. Current strategies to generate human mesenchymal stem cells in vitro. Stem Cells Int. 2018;2018:6726185.
Zhao C, Ikeya M. Generation and applications of induced pluripotent stem cell-derived mesenchymal stem cells. Stem Cells Int. 2018;2018:9601623.
Abdal Dayem A, Lee SB, Kim K, et al. Production of mesenchymal stem cells through stem cell reprogramming. Int J Mol Sci. 2019;20:1922.
Lian Q, Zhang Y, Zhang J, et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation. 2010;121:1113–23.
Kimbrel EA, Kouris NA, Yavanian GJ, et al. Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells Dev. 2014;23:1611–24.
Zhang Y, Liao S, Yang M, et al. Improved cell survival and paracrine capacity of human embryonic stem cell-derived mesenchymal stem cells promote therapeutic potential for pulmonary arterial hypertension. Cell Transplant. 2012;21:2225–39.
Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–72.
Okita K, Matsumura Y, Sato Y, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8:409–12.
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8:315–7.
Arpke RW, Darabi R, Mader TL, et al. A new immuno-, dystrophin-deficient model, the NSG-mdx(4Cv) mouse, provides evidence for functional improvement following allogeneic satellite cell transplantation. Stem Cells. 2013;31:1611–20.
Turinetto V, Vitale E, Giachino C. Senescence in human mesenchymal stem cells: functional changes and implications in stem cell-based therapy. Int J Mol Sci. 2016;17:1164.
Kang R, Zhou Y, Tan S, et al. Mesenchymal stem cells derived from human induced pluripotent stem cells retain adequate osteogenicity and chondrogenicity but less adipogenicity. Stem Cell Res Ther. 2015;6:144.
Xu M, Shaw G, Murphy M, et al. Induced pluripotent stem cell-derived mesenchymal stromal cells are functionally and genetically different from bone marrow-derived mesenchymal stromal cells. Stem Cells. 2019;37:754–65.
Sassoli C, Pini A, Chellini F, et al. Bone marrow mesenchymal stromal cells stimulate skeletal myoblast proliferation through the paracrine release of VEGF. PLoS ONE. 2012;7:e37512.
Kumar P, Kandoi S, Misra R, et al. The mesenchymal stem cell secretome: a new paradigm towards cell-free therapeutic mode in regenerative medicine. Cytokine Growth Factor Rev. 2019;46:1–9.
Li H, Mittal A, Makonchuk DY, et al. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum Mol Genet. 2009;18:2584–98.
Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted role of the urokinase-type plasminogen-activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications. Front Oncol. 2018;8:24.
Bonavaud S, Charriere-Bertrand C, Rey C, et al. Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion. J Cell Sci. 1997;110:1083–9.
Wells JM, Strickland S. Regulated localization confers multiple functions on the protease urokinase plasminogen activator. J Cell Physiol. 1997;171:217–25.
Chazaud B, Bonavaud S, Plonquet A, et al. Involvement of the [uPAR: uPA: PAI-1: LRP] complex in human myogenic cell motility. Exp Cell Res. 2000;258:237–44.
Fibbi G, Barletta E, Dini G, et al. Cell invasion is affected by differential expression of the urokinase plasminogen activator/urokinase plasminogen activator receptor system in muscle satellite cells from normal and dystrophic patients. Lab Invest. 2001;81:27–39.
Suelves M, Vidal B, Serrano AL, et al. uPA deficiency exacerbates muscular dystrophy in MDX mice. J Cell Biol. 2007;178:1039–51.
Lin L, Gårdsvoll H, Huai Q, et al. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor. J Biol Chem. 2021;285:10982–92.
Sakai-Takemura F, Narita A, Masuda S, et al. Premyogenic progenitors derived from human pluripotent stem cells expand in floating culture and differentiate into transplantable myogenic progenitors. Sci Rep. 2018;8:6555.
Sakai-Takemura F, Nogami K, Elhussieny A, et al. Prostaglandin EP2 receptor downstream of NOTCH signaling inhibits differentiation of human skeletal muscle progenitors in differentiation conditions. Commun Biol. 2020;3:182.
Shiomi K, Kiyono T, Okamura K, et al. CDK4 and cyclin D1 allow human myogenic cells to recapture growth property without compromising differentiation potential. Gene Ther. 2011;18:857–66.
We appreciate Kathrine Ono for editing English.
A.E. is supported by the Channel System Program (CPS) of the Egyptian and Japanese governments. This study was supported by the Japan Agency for Medical Research and Development (AMED) (19bm0804005h0103), (2) Grants‐in‐aid for Scientific Research (C) (16K08725, 19K07519) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, and (3) Intramural Research Grants (30-9, 2-6) for Neurological and Psychiatric Disorders of NCNP.
Ethics approval and consent to participate
All experimental protocols were approved by the Experimental Animal Care and Use Committee of the National Institute of Neuroscience (NIN), National Center of Neurology and Psychiatry (NCNP), Japan. The experiments were performed according to the guidelines of the NIN.
Consent for publication
The authors declare no competing interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
. No detectable expression of pluripotency factors OCT3/4, NANOG, or SOX2 in iMSCs. Figure S2 (related to Fig. 2). Proliferation of human myogenic cells was stimulated by coculture with iMSCs or BM-MSCs. Figure S3 (related to Fig. 3). Representative immunohistochemistry of cross-sections of the TA muscles of NSG-mdx4Cv mice or NOD/Scid mice transplanted with Hu5/KD3 cells, or Hu5/KD3 cells with iMSCs (i.p.). Figure S4. Grip test and treadmill test of mdx mice and Sirius staining of diaphragm in NSG-mdx4cv mice injected intraperitoneally with iMSCs or BM-MSCs. Figure S5.BM-MSCs or iMSCs did not affect fiber size in TA muscles of NSG-mdx4Cv or mdx mice. Figure S6 (related to Table 1). iMSCs and BM-MSCs secrete similar but distinct sets of cytokines. Figure S7 (related to Figure 4). Phase contrast images of Hu5/KD3 cells just after scratching with a pipette tip (0 h) and 6 h later (6 h).
About this article
Cite this article
Elhussieny, A., Nogami, K., Sakai-Takemura, F. et al. Mesenchymal stem cells derived from human induced pluripotent stem cells improve the engraftment of myogenic cells by secreting urokinase-type plasminogen activator receptor (uPAR). Stem Cell Res Ther 12, 532 (2021). https://doi.org/10.1186/s13287-021-02594-1
- Human iPS cells
- Mesenchymal stem cells
- Skeletal muscle
- Muscle progenitors
- Cell transplantation
- Duchenne muscular dystrophy (DMD)
- Urokinase-type plasminogen activator (uPA)
- uPA receptor (uPAR)